Celcuity Prices Upsized $500M Convertible Notes Offering at 40% Premium to Fund Commercialization

summarizeSummary

Celcuity priced an upsized $500 million convertible senior notes offering with a 40% conversion premium, securing substantial capital for debt repayment and commercialization efforts following recent positive clinical trial results and a stock decline.

check_boxKey Events · Financing and Capital Events · CELC

• Upsized Convertible Notes Offering Priced

  Celcuity priced $500 million in 0.250% convertible senior notes due 2032, up from an initial $400 million, with a potential total of $575 million if the over-allotment option is fully exercised.

• Favorable Conversion Premium

  The notes feature an initial conversion price of approximately $124.53 per share, representing a 40.0% premium over the last reported stock price of $88.95 on June 3, 2026.

• Strategic Use of Proceeds

  Net proceeds of approximately $484.3 million (or $557.0 million with over-allotment) will be used to repay outstanding loan obligations and for general corporate purposes, including clinical trial and commercial launch expenditures for gedatolisib.

• Capital Secured Post-Stock Decline

  This financing follows a recent 25% drop in Celcuity's shares after detailed Phase 3 trial results, providing critical capital for the company's ongoing development and commercialization plans.

auto_awesomeAnalysis · CELC · Industrial Applications And Services

Celcuity has finalized the pricing for an upsized $500 million offering of 0.250% convertible senior notes, potentially increasing to $575 million with the over-allotment option. This significant capital raise, representing approximately 11.5% of the company's market capitalization, is critical for Celcuity, especially following a recent 25% stock plunge after detailed Phase 3 trial results. The notes are priced with an initial conversion premium of 40% above the last reported stock price, meaning conversion into equity would only occur if the stock appreciates significantly. Proceeds will be used to repay existing debt and fund working capital, including crucial clinical trial and commercial launch expenditures for its lead drug candidate, gedatolisib, which recently received FDA Priority Review and showed positive Phase 3 results. This financing provides essential runway for the company's commercialization efforts.